Initial combination therapy for patients with pulmonary arterial hypertension (PAH): a budget impact analysis from the perspective of the Italian national healthcare system

Marco Barbieri, Stefano Ghio, Michele D’Alto, Carlo Albera, Renato Carignola, Massimiliano Mulè, Patrizio Vitulo, Miriam Vighini, Rosaria Silvestri, William Zamboni, Carmine Dario Vizza

Research output: Contribution to journalArticle

Abstract

Background: Initial combination therapy in patients with pulmonary arterial hypertension (PAH) WHO functional class (FC) II or III has demonstrated clinical benefits over initial monotherapy. The objective of this study is to compare the financial impact of initial combination therapy with initial monotherapy for incident patients with PAH in Italy. Methods: A 3-year budget impact model compared a ‘status quo’ scenario of initial monotherapy with an endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitor (PDE5i) or prostanoid, with a ‘new’ scenario involving initial combination therapy, using Italian national healthcare system (NHS) data for incident patients with PAH WHO FC II or III. The hospitalisation hazard ratio (HHR) from the AMBITION study and expert panel advice on therapy use were employed. Univariate sensitivity analyses were performed. Results: A difference in costs of €16,070 favouring the ‘new’ scenario (initial combination therapy) was observed, and attributed to 101 fewer hospitalisations over 3 years. Sensitivity analyses showed that costs were driven by the proportion of patients receiving ERAs versus PDE5i, hospitalisation costs and prostanoid dose. Conclusion: Initial combination therapy instead of monotherapy could reduce the number and cost of hospitalisations without an increase in the total costs to the Italian NHS.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalExpert Opinion on Orphan Drugs
Volume6
Issue number1
DOIs
Publication statusPublished - Jan 2 2018

Fingerprint

Budgets
Pulmonary Hypertension
Delivery of Health Care
Costs and Cost Analysis
Hospitalization
Phosphodiesterase 5 Inhibitors
Prostaglandins
Therapeutics
Italy

Keywords

  • Cost
  • hospitalisation
  • initial combination therapy
  • pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Initial combination therapy for patients with pulmonary arterial hypertension (PAH) : a budget impact analysis from the perspective of the Italian national healthcare system. / Barbieri, Marco; Ghio, Stefano; D’Alto, Michele; Albera, Carlo; Carignola, Renato; Mulè, Massimiliano; Vitulo, Patrizio; Vighini, Miriam; Silvestri, Rosaria; Zamboni, William; Vizza, Carmine Dario.

In: Expert Opinion on Orphan Drugs, Vol. 6, No. 1, 02.01.2018, p. 1-7.

Research output: Contribution to journalArticle

Barbieri, Marco ; Ghio, Stefano ; D’Alto, Michele ; Albera, Carlo ; Carignola, Renato ; Mulè, Massimiliano ; Vitulo, Patrizio ; Vighini, Miriam ; Silvestri, Rosaria ; Zamboni, William ; Vizza, Carmine Dario. / Initial combination therapy for patients with pulmonary arterial hypertension (PAH) : a budget impact analysis from the perspective of the Italian national healthcare system. In: Expert Opinion on Orphan Drugs. 2018 ; Vol. 6, No. 1. pp. 1-7.
@article{45575aca3010431db5752dda1294e329,
title = "Initial combination therapy for patients with pulmonary arterial hypertension (PAH): a budget impact analysis from the perspective of the Italian national healthcare system",
abstract = "Background: Initial combination therapy in patients with pulmonary arterial hypertension (PAH) WHO functional class (FC) II or III has demonstrated clinical benefits over initial monotherapy. The objective of this study is to compare the financial impact of initial combination therapy with initial monotherapy for incident patients with PAH in Italy. Methods: A 3-year budget impact model compared a ‘status quo’ scenario of initial monotherapy with an endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitor (PDE5i) or prostanoid, with a ‘new’ scenario involving initial combination therapy, using Italian national healthcare system (NHS) data for incident patients with PAH WHO FC II or III. The hospitalisation hazard ratio (HHR) from the AMBITION study and expert panel advice on therapy use were employed. Univariate sensitivity analyses were performed. Results: A difference in costs of €16,070 favouring the ‘new’ scenario (initial combination therapy) was observed, and attributed to 101 fewer hospitalisations over 3 years. Sensitivity analyses showed that costs were driven by the proportion of patients receiving ERAs versus PDE5i, hospitalisation costs and prostanoid dose. Conclusion: Initial combination therapy instead of monotherapy could reduce the number and cost of hospitalisations without an increase in the total costs to the Italian NHS.",
keywords = "Cost, hospitalisation, initial combination therapy, pulmonary arterial hypertension",
author = "Marco Barbieri and Stefano Ghio and Michele D’Alto and Carlo Albera and Renato Carignola and Massimiliano Mul{\`e} and Patrizio Vitulo and Miriam Vighini and Rosaria Silvestri and William Zamboni and Vizza, {Carmine Dario}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/21678707.2018.1411259",
language = "English",
volume = "6",
pages = "1--7",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Initial combination therapy for patients with pulmonary arterial hypertension (PAH)

T2 - a budget impact analysis from the perspective of the Italian national healthcare system

AU - Barbieri, Marco

AU - Ghio, Stefano

AU - D’Alto, Michele

AU - Albera, Carlo

AU - Carignola, Renato

AU - Mulè, Massimiliano

AU - Vitulo, Patrizio

AU - Vighini, Miriam

AU - Silvestri, Rosaria

AU - Zamboni, William

AU - Vizza, Carmine Dario

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Background: Initial combination therapy in patients with pulmonary arterial hypertension (PAH) WHO functional class (FC) II or III has demonstrated clinical benefits over initial monotherapy. The objective of this study is to compare the financial impact of initial combination therapy with initial monotherapy for incident patients with PAH in Italy. Methods: A 3-year budget impact model compared a ‘status quo’ scenario of initial monotherapy with an endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitor (PDE5i) or prostanoid, with a ‘new’ scenario involving initial combination therapy, using Italian national healthcare system (NHS) data for incident patients with PAH WHO FC II or III. The hospitalisation hazard ratio (HHR) from the AMBITION study and expert panel advice on therapy use were employed. Univariate sensitivity analyses were performed. Results: A difference in costs of €16,070 favouring the ‘new’ scenario (initial combination therapy) was observed, and attributed to 101 fewer hospitalisations over 3 years. Sensitivity analyses showed that costs were driven by the proportion of patients receiving ERAs versus PDE5i, hospitalisation costs and prostanoid dose. Conclusion: Initial combination therapy instead of monotherapy could reduce the number and cost of hospitalisations without an increase in the total costs to the Italian NHS.

AB - Background: Initial combination therapy in patients with pulmonary arterial hypertension (PAH) WHO functional class (FC) II or III has demonstrated clinical benefits over initial monotherapy. The objective of this study is to compare the financial impact of initial combination therapy with initial monotherapy for incident patients with PAH in Italy. Methods: A 3-year budget impact model compared a ‘status quo’ scenario of initial monotherapy with an endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitor (PDE5i) or prostanoid, with a ‘new’ scenario involving initial combination therapy, using Italian national healthcare system (NHS) data for incident patients with PAH WHO FC II or III. The hospitalisation hazard ratio (HHR) from the AMBITION study and expert panel advice on therapy use were employed. Univariate sensitivity analyses were performed. Results: A difference in costs of €16,070 favouring the ‘new’ scenario (initial combination therapy) was observed, and attributed to 101 fewer hospitalisations over 3 years. Sensitivity analyses showed that costs were driven by the proportion of patients receiving ERAs versus PDE5i, hospitalisation costs and prostanoid dose. Conclusion: Initial combination therapy instead of monotherapy could reduce the number and cost of hospitalisations without an increase in the total costs to the Italian NHS.

KW - Cost

KW - hospitalisation

KW - initial combination therapy

KW - pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=85037995050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037995050&partnerID=8YFLogxK

U2 - 10.1080/21678707.2018.1411259

DO - 10.1080/21678707.2018.1411259

M3 - Article

AN - SCOPUS:85037995050

VL - 6

SP - 1

EP - 7

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 1

ER -